# **FORM**



UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

# FORM D

NOTICE OF SALE OF SECURITIES PURSUANT TO REGULATION D **SECTION 4(6), AND/OR** 

OMB Number: 3235-0076 Expires: November 30, 2001 Eştimated average burden

OMB APPROVAL

200 hours per response . .

RECEIVED

MAR 0

SEC USE ONLY Prefix Serial DATE RECEIVED

	UNIFORM LIMITED OFFERING	EXEMPTION
Name of Offering ( check if t	his is an amendment and name has changed, and	d indicate change.) /328976
Filing Under (Check box(es) tha	apply):  Rule 504 Rule 505 Rule	506 Section 4(6) ULOE
Type of Filing: X New Filing	☐ Amendment	•
	A. BASIC IDENTIFICATION	DATA
1. Enter the information requeste	d about the issuer	
Name of Issuer (☐ check if this	is an amendment and name has changed, and i	ndicate change.)
Riley Genomics, Inc.		
Address of Executive Offices 755 Research Parkway, Suite 4	(Number and Street, City, State, Zip 35, Oklahoma City, OK 73104	Code) Telephone Number (Including Area Code) (405) 271-5081
Address of Principal Business O (if different from Executive Office		Code) Telephone Number (Including Area Code) Same as above. PROCESSED
Brief Description of Business		CE32ED
<u>=</u>	ting and sale of biopharmaceutical products.	E MAR 1 9 2007
Type of Business Organization		
□ corporation	☐ limited partnership, already formed	THOMSON Xother (please specify) NANCIAL
☐ business trust	☐ limited partnership, to be formed	contex (product special product (product special product speci
Actual or Estimated Date of Inco Jurisdiction of Incorporation or G	0 1 0	ear 7  XActual
	CN for Canada; FN for other fore	ign jurisdiction)

#### GENERAL INSTRUCTIONS

#### Federal:

Who Must File: All issuers making an offering of securities in reliance on an exemption under Regulation D or Section 4(6), 17 CFR 230.501 ct seq. or 15 U.S.C. 77d(6).

When To File: A notice must be filed no later than 15 days after the first sale of securities in the offering. A notice is deemed filed with the U.S. Securities and Exchange Commission (SEC) on the earlier of the date it is received by the SEC at the address given below or, if received at that address after the date on which it is due, on the date it was mailed by United States registered or certified mail to that address.

Where To File: U.S. Securities and Exchange Commission, 450 Fifth Street, N.W., Washington, D.C. 20549.

Copies Required: Five (5) copies of this notice must be filed with the SEC, one of which must be manually signed. Any copies not manually signed must be photocopies of the manually signed copy or bear typed or printed signatures.

Information Required: A new filing must contain all information requested. Amendments need only report the name of the issuer and offering, any changes thereto, the information requested in Part C, and any material changes from the information previously supplied in Parts A and B. Part E and the Appendix need not be filed with the SEC.

Filing Fee: There is no federal filing fee.

## State:

This notice shall be used to indicate reliance on the Uniform Limited Offering Exemption (ULOE) for sales of securities in those states that have adopted ULOE and that have adopted this form. Issuers relying on ULOE must file a separate notice with the Securities Administrator in each state where sales are to be, or have been made. If a state requires the payment of a fee as a precondition to the claim for the exemption, a fee in the proper amount shall accompany this form. This notice shall be filed in the appropriate states in accordance with state law. The Appendix to the notice constitutes a part of this notice and must be completed.

ATTENTION:

Failure to file notice in the appropriate states will not result in a loss of the federal exemption. Conversely, failure to file the appropriate federal notice will not result in a loss of an available state exemption unless such exemption is predicated on the filing of a federal notice.

> Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1972 (2/99) 1 of 8

### **BASIC IDENTIFICATION DATA** Enter the information requested for the following: Each promoter of the issuer, if the issuer has been organized within the past five years; Each beneficial owner having the power to vote or dispose, or direct the vote or disposition of, 10% or more of a class of equity securities of the issuer: Each executive officer and director of corporate issuers and of corporate general and managing partners of partnership issuers; and • Each general and managing partner of partnership issuers. ☐ Beneficial Owner ☐ Executive Officer □ Director ☐ General and/or Managing Partner Full Name (Last name first, if individual) Centola, Michael, Ph.D. Business or Residence Address (Number and Street, City, State, Zip Code) 755 Research Parkway, Suite 435, Oklahoma City, OK 73104 Check Box(es) that Apply: Promoter ☐ Beneficial Owner ☐ Executive Officer □ Director ☐ General and/or Managing Partner Full Name (Last name first, if individual) Hagstrom, William A. Business or Residence Address (Number and Street, City, State, Zip Code) 800 Research Parkway, Suite 330, Oklahoma City, OK 73104 Check Box(es) that Apply: Promoter ☐ Beneficial Owner ☐ Executive Officer ☐ Director ☐ General and/or Managing Partner Full Name (Last name first, if individual) Sutton, Christopher, Ph.D. Business or Residence Address (Number and Street, City, State, Zip Code) 755 Research Parkway, Suite 435, Oklahoma City, OK 73104 ☐ Beneficial Owner ☐ Executive Officer Check Box(es) that Apply: ☐ Promoter ☐ Director ☐ General and/or Managing Partner Full Name (Last name first, if individual) MDV VIII, L.P., as nominee for MDV VIII, L.P., MDV VIII Leaders' Fund, L.P., and MDV ENF VIII, L.P. Business or Residence Address (Number and Street, City, State, Zip Code) c/o Mohr, Davidow Ventures, 3000 Sand Hill Road, Bldg. 3, Suite 290, Menlo Park, CA 94025 Check Box(es) that Apply: ☑ Beneficial Owner ☐ Executive Officer ☐ Director ☐ Promoter ☐ General and/or Managing Partner Full Name (Last name first, if individual) Oklahoma Medical Research Foundation Business or Residence Address (Number and Street, City, State, Zip Code) 755 Research Parkway, Suite 410, Oklahoma City, OK 73104 ☑ Beneficial Owner ☐ Executive Officer Check Box(es) that Apply: ☐ Promoter ☐ Director ☐ General and/or Managing Partner Full Name (Last name first, if individual) Centola, Navara, M.D. Business or Residence Address (Number and Street, City, State, Zip Code) 5206 Daybrook Circle, Apt. 249, Rosedale, MD 21237 Check Box(es) that Apply: ☐ Beneficial Owner ☐ Executive Officer ☐ Director □ Promoter ☐ General and/or Managing Partner

Full Name (Last name first, if individual)

Riley Genomics, Inc., an Oklahoma corporation (subsequently merged with and in to Riley Genomics, Inc., a Delaware corporation)

Business or Residence Address (Number and Street, City, State, Zip Code)

755 Research Parkway, Suite 435, Oklahoma City, OK 73104

				B. INF	ORMAT	ION ABO	UT OFF	ERING					
1 Head	ha iaaa- aa	ld andaa	s tha ianua	مع المسمورة	aall ta ma		tad imposts	. wa in thia	offering?			Yes	
1. Has t	he issuer so	ia, or does				ix, Colum			_		• • • • • • • • • • • • • • • • • • • •		⊠
<b>2</b> 117 .								_				<b>#</b> 25	100
2. What	is the mini	mum inve	stment tha	t will be a	ccepted fr	om any in	dividual?.		••••••			\$ 25,4 Yes	
3. Does	the offering	g permit jo	oint owner	ship of a s	ingle unit	?			•••••			$\boxtimes$	
sion o to be list th	the informant or similar results in the listed is an	muneration associated ne broker	i for solicit person or or dealer. I	ation of pu agent of a If more th	irchasers in broker of an five (5)	n connection dealer reports to the connection of	on with sal gistered with one be listed	es of secur th the SE	rities in the C and/or v	e offering. I with a state	If a person or states	n i,	
Full Name	(Last name	first, if in	dividual)							·	•		
N/A													
Business o	r Residence	Address	(Number a	nd Street,	City, Stat	e, Zip Coo	ie)						
Name of A	ssociated B	roker or I	Dealer										-
	hich Perso 'All States"						sers						States
[AL]	[AK]	[AZ]	[AR]	[CA]	[CO]	[CT]	[DE]	[DC]	[FL]	[GA]	 [HI]	ID)	
[IL]	[IN]	[IA]	[KS]	[KY]	[LA]	[ME]	[MD]	[MA]	[MI]	[MN]	[MS]	[MC	=
[MT]	[NE]	[NV]	[NH]	[NJ]	[NM]	[NY]	[NC]	[ND]	[0H]	[OK]	[OR]	[PA	_
[RI]	(SC)	[SD]	(TN)	[TX]	[UT]	[VT]	[VA]	[WA]	[WV]	[WI]	[WY]	[PR	_
Full Name	(Last name	first, if in	dividual)										
Business o	r Residence	Address	(Number a	and Street,	City, Stat	e, Zip Coo	de)			· · · · · ·			
Name of A	ssociated B	Broker or I	Dealer										
	hich Perso 'All States"												States
[AL]	[AK]	[AZ]	[AR]	[CA]	[CO]	[CT]	[DE]	[DC]	[FL]	[GA]	[HI]	[ID	]
[IL]	[IN]	[IA]	[KS]	[KY]	[LA]	[ME]	[MD]	[MA]	[MI]	[MN]	[MS]	[MC	)]
[MT]	[NE]	[NV]	[NH]	[NJ]	[NM]	[NY]	[NC]	[ND]	[OH]	[OK]	[OR]	[PA	.]
[RI]	[SC]	[SD]	[TN]	[XT]	[UT]	[VT]	[VA]	[WA]	[WV]	[WI]	[WY]	[PR	]
Full Name	(Last name	first, if in	dividual)										
Business o	r Residence	Address	(Number a	nd Street,	City, Stat	e, Zip Coo	de)				-		
Name of A	ssociated E	Broker or I	Dealer										
	hich Perso												a
(Cneck '	'All States" [AK]	or check i	individual [AR]	States)	[CO]	[CT]	[DE]	[DC]	[FL]	[GA]	 [HI]	□ All [ID	
[IL]	[IN]	[IA]	[KS]	[KY]	[LA]	[ME]	[DE] [MD]	[MA]	[MI]	[MN]	[MS]	[MC	
[MT]	[NE]	[NV]	[NH]	[NJ]	[NM]	[NY]	[NC]	[ND]	[OH]	[OK]	[OR]	[PA	_
[RI]	[SC]	[SD]	[TN]	[TX]	[UT]	[VT]	[VA]	[WA]	[WV]	[WI]	[WY]	[PR	
£ J	, -J		blank she								f .1	ί- ν.	
		(030	. Oldlik Silk	or cop	, and use	3 of 8	copies of	ans succi,	as neces	y . j			

	C. OFFERING PRICE, NUMBER OF INVESTORS, EXPENSES AND USE	OF PROCEED	S
1.	Enter the aggregate offering price of securities included in this offering and the total amount already sold. Enter "0" if answer is "none" or "zero." If the transaction is an exchange offering, check this box $\square$ and indicate in the columns below the amounts of the securities offered for exchange and already exchanged.		
	Type of Security	Aggregate Offering Price	Amount Already Sold
	Debt	<b>\$</b>	\$
	Equity	\$ 5,082,101	\$ 5,082,101
	☐ Common		
	Convertible Securities (including warrants)	\$	\$
	Partnership Interests	<u>\$</u>	\$
	Other (Specify)	<b>\$</b>	\$
	Total	\$5,082,101	\$.5,082,101
	Answer also in Appendix, Column 3, if filing under ULOE.		
2.	Enter the number of accredited and non-accredited investors who have purchased securities in this offering and the aggregate dollar amounts of their purchases. For offerings under Rule 504, indicate the number of persons who have purchased securities and the aggregate dollar amount of their purchases on the total lines. Enter "0" if answer is "none" or "zero."		
	•	Number Investors	Aggregate Dollar Amoun of Purchases
	Accredited Investors	4	\$_5,082,101
	Non-accredited Investors		\$
	Total (for filings under Rule 504 only)		\$
	Answer also in Appendix, Column 4, if filing under ULOE.		
3.	If this filing is for an offering under Rule 504 or 505, enter the information requested for all securities sold by the issuer, to date, in offerings of the types indicated, in the twelve (12) months prior to the first sale of securities in this offering. Classify securities by type listed in Part C - Question 1.		
	Type of offering	Type of Security	Dollar Amount Sold
	Rule 505		\$
	Regulation A		\$
	Rule 504		\$
4.	a. Furnish a statement of all expenses in connection with the issuance and distribution of the securities in this offering. Exclude amounts relating solely to organization expenses of the issuer. The information may be given as subject to future contingencies. If the amount of an expenditure is not known, furnish an estimate and check the box to the left of the estimate.		
	Transfer Agent's Fees	<b>\</b>	] <b>\$</b>
	Printing and Engraving Costs	🗵	\$ 150.00
	Legal Fees (Fees incurred by Company Counsel and Investors Counsel)	<b></b>	\$ 80,000.00
	Due Diligence Fees	×	\$ 40,000.00
	Accounting Fees	<b>E</b>	1 \$
	Engineering Fees	×	] \$
	Sales Commissions (specify finders' fees separately)		] \$
	Other Expenses (identify) Filing Fees		
	Total	I⊽	1 \$ 121 150 00

b. Enter the difference between the aggregate offering price given in response to Part C - Question 1 and total expenses furnished in response to Part C - Question 4.a. This difference is the "adjusted gross proceeds to the issuer."  5. Indicate below the amount of the adjusted gross proceeds to the issuer used or proposed to be used for each of the purposes shown. If the amount for any purpose is not known, furnish an estimate and check the box to be left of the estimate. The total of the payments listed must equal the adjusted gross proceeds to the issuer set forth in response to Part C - Question 4.b above.  Payments to Officers, Directors, & Affiliates  Salaries and fees		C. OFFERING PRICE, NUMBER OF INVESTORS, EXPENSES AND	USE O	F PROCEE	DS	
used for each of the purposes shown. If the amount for any purpose is not known, furnish an estimate and check the box to the left of the estimate. The total of the payments listed must equal the adjusted gross proceeds to the issuer set forth in response to Part C - Question 4.b above.    Payments T Officers, Directors, & Affiliates		tion 1 and total expenses furnished in response to Part C - Question 4.a. This difference is	the		\$ <u>4.9</u>	60,951
Purchase of real estate	5.	used for each of the purposes shown. If the amount for any purpose is not known, furnish estimate and check the box to the left of the estimate. The total of the payments listed must e	h an qual ve.	Officers, Directors, &		
Purchase, rental or leasing and iunstallation of machinery and equipment		Salaries and fees	⊠\$_		⊠\$	
Construction or leasing of plant buildings and facititities		Purchase of real estate	⊠\$_	0	<b>⊠</b> \$	0
Acquisition of other businesses (including the value of securities involved in this offering that may be used in exchange for the assets or securities of another issuer pursuant to a merger)		Purchase, rental or leasing and iunstallation of machinery and equipment	⊠\$_	0	⊠\$	0
offering that may be used in exchange for the assets or securities of another issuer pursuant to a merger)		Construction or leasing of plant buildings and facitlities	⊠\$_	0	<b>⊠</b> \$	0
Working capital (Including product development)  Other (specify):  S\$ 0 S\$ 4,678,850  Other (specify):  S\$ 0 S\$ 0  Column Totals		offering that may be used in exchange for the assets or securities of another	⊠\$_	0	⊠\$	0
Other (specify):    S		Repayment of indebtedness	<b>⊠</b> \$_	25,422	⊠\$_2	56,679
Column Totals		Working capital (Including product development)	<b>⊠</b> \$_	0	<b>⊠</b> \$ 4,6	78,850
Total Payments Listed (column totals added)  D. FEDERAL SIGNATURE  The issuer has duly caused this notice to be signed by the undersigned duly authorized person. If this notice is filed under Rule 505, to following signature constitutes an undertaking by the issuer to furnish to the U.S. Securities and Exchange Commission, upon written equest of its staff, the information furnished by the issuer to any non-accredited investor pursuant to paragraph (b)(2) of Rule 502.  Issuer (Print or Type)  Signature  Date  Riley Genomics, Inc.  March 5, 2007  Title of Signer (Print or Type)		Other (specify):	⊠\$_	0	<b>⊠</b> \$	
Total Payments Listed (column totals added)  D. FEDERAL SIGNATURE  The issuer has duly caused this notice to be signed by the undersigned duly authorized person. If this notice is filed under Rule 505, to following signature constitutes an undertaking by the issuer to furnish to the U.S. Securities and Exchange Commission, upon written a quest of its staff, the information furnished by the issuer to any non-accredited investor pursuant to paragraph (b)(2) of Rule 502.  Issuer (Print or Type)  Signature  Date  March 5, 2007  Title of Signer (Print or Type)			⊠\$_	0	⊠\$	0
D. FEDERAL SIGNATURE  The issuer has duly caused this notice to be signed by the undersigned duly authorized person. If this notice is filed under Rule 505, to following signature constitutes an undertaking by the issuer to furnish to the U.S. Securities and Exchange Commission, upon written a quest of its staff, the information furnished by the issuer to any non-accredited investor pursuant to paragraph (b)(2) of Rule 502.  Issuer (Print or Type)  Signature  Date  Riley Genomics, Inc.  March 5, 2007  Title of Signer (Print or Type)		Column Totals	<b>⊠</b> \$_	25,422	<b>⊠</b> \$ 4,9	35,529
The issuer has duly caused this notice to be signed by the undersigned duly authorized person. If this notice is filed under Rule 505, to following signature constitutes an undertaking by the issuer to furnish to the U.S. Securities and Exchange Commission, upon written a quest of its staff, the information furnished by the issuer to any non-accredited investor pursuant to paragraph (b)(2) of Rule 502.  Issuer (Print or Type)  Signature  Date  Riley Genomics, Inc.  March 5, 2007  Title of Signer (Print or Type)		Total Payments Listed (column totals added)		<b>⊠</b> \$ 4,9	960,951	-
following signature constitutes an undertaking by the issuer to furnish to the U.S. Securities and Exchange Commission, upon written a quest of its staff, the information furnished by the issuer to any non-accredited investor pursuant to paragraph (b)(2) of Rule 502.  Issuer (Print or Type)  Signature  Date  March 5, 2007  Title of Signer (Print or Type)		D. FEDERAL SIGNATURE	· ·			
Riley Genomics, Inc.  March 5, 2007  Name of Signer (Print or Type)  Title of Signer (Print or Type)	foll	owing signature constitutes an undertaking by the issuer to furnish to the U.S. Securities and	Exchan	ige Commissi	ion, upon	written re-
Name of Signer (Print or Type)  Title of Signer (Print or Type)		I half i half			5 2007	
William A. Hagstrom Chief Executive Officer				pviuicii	D, 2001	
	Wil	liam A. Hagstrom Chief Executive Officer				

# -ATTENTION-

Intentional misstatements or omissions of fact constitute federal criminal violations. (See 18 U.S.C. 1001.)

k .	£		
	E. STATE SIGNATURE		
1.	Is any party described in 17 CFR 230.262 presently subject to any of the disqualification provisions of such rule?	Yes □	No ⊠
	See Appendix, Column 5, for state response.	_	
2.	The undersigned issuer hereby undertakes to furnish to any state administrator of any state in which this notice is filed. Form D (17 CFR 239.500) at such times as required by state law.	, a noti	ice on
3.	The undersigned issuer hereby undertakes to furnish to the state administrators, upon written request, information furn issuer to offerees	ished l	by the

4. The undersigned issuer represents that the issuer is familiar with the conditions that must be satisfied to be entitled to the Uniform Limited Offering Exemption (ULOE) of the state in which this notice is filed and understands that the issuer claiming the availability of this exemption has the burden of establishing that these conditions have been satisfied.

The issuer has read this notification and knows the contents to be true and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

Issuer (Print or Type)	Signature	Date
Riley Genomics, Inc. Name of Signer (Print or Type)	Title of Signer (Print or Type)	March 5, 2007
William A. Hagstrom	Chief Executive Officer	

## Instruction:

Print the name and title of the signing representative under his signature for the state portion of this form. One copy of every notice on Form D must be manually signed. Any copies not manually signed must be photocopies of the manually signed copy or bear typed or printed signatures.

APPENDIX

1	2		3	4					5		
	Intend to sell and aggregate to non-accredited investors in State (Part B-Iteml)  Type of security and aggregate offering price offered in State (Part C-Iteml)				Disqualification under State ULOE (if yes, attach explanation of waiver granted) (Part E-Item 1)						
State	Yes	No		Number of Accredited Investors	Amount	Number of Non-Accredited Investors	Amount	Yes	No		
AL							-				
AK											
AZ					-						
AR											
CA		х	Series A Preferred Stock	1	\$5,000,000						
СО											
СТ											
DE											
DC									·		
FL											
GA											
HI											
ID		 									
IL											
IN											
IA											
KS											
KY				· · · ·							
LA											
ME											
MD				<del>"</del>							
MA											
MI											
MN		<u> </u>									
MS											
МО								<u> </u>			

APPENDIX

1	2		3		5					
	to non-a investor	I to sell ccredited s in State I-Item1)	Type of security and aggregate offering price offered in State (Part C-Item1)		Type of investor and amount purchased in State  (Part C-Item 2)				Disqualification under State ULOE (if yes, attach explanation of waiver granted) (Part E-Item 1)	
State	Yes	No		Number of Accredited Investors	Amount	Number of Non-Accredited Investors	Amount	Yes	No	
MT		<u> </u>							<u></u>	
NE										
NV										
NH										
NJ										
NM										
NY										
NC										
ND										
ОН										
OK		X	Series A Preferred Stock	3	82,101					
OR										
PA										
RI										
SC					_					
SD										
TN										
TX										
UT										
VT										
VA										
WA										
wv										
WI										
WY										
PR								FN		